Glaukos Corporation Q4 2025 Earnings Call Summary

Record 2025 performance was primarily driven by the rapid adoption of iDose TR, which generated approximately $136 million in its first full year. Management attributes U.S. glaucoma growth to the successful advancement of the interventional treatment paradigm, shifting the standard of care toward earlier surgical intervention. International glaucoma net sales grew 13% on a constant currency basis in the fourth quarter, reflecting broad-based scaling of infrastructure despite emerging competitive tria ...